Abstract: The present invention provides processes for preparing nal-opiates without the isolation of intermediates. In general, the process provides for alkylation and reduction in the same pot to give the nal-opiate.

Abstract: Containers and methods for disposing unused pharmaceutical product are disclosed. Each container (100, 200, 300) may include a container body (104, 204, 304) with an internal chamber (116, 216, 316) for storing pharmaceutical product, along with a cover (124, 224, 324) for selectively limiting access to the chamber (116, 216, 316). An encapsulation component (128, 228, 328) may be selectively disposable within the chamber (116, 216, 316), and may be operable to encapsulate the pharmaceutical product within the container (100, 200, 300). For instance, the encapsulation component (128, 228, 328) may melt and/or flow into contact with the pharmaceutical product and thereafter solidify to encapsulate the pharmaceutical product. The encapsulation component (128, 228, 328) may melt and thereafter solidify between the cover (124, 224, 324) and shell (104, 204, 304) to limit removal of the cover (124, 224, 324) from the shell (104, 204, 304).

Abstract: The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.

Abstract: A pharmaceutical product supply in the form of a container (e.g., secondary packaging) and a pharmaceutical product receiver (e.g., primary packaging) is disclosed. The pharmaceutical product receiver may include a plurality of pockets or receptacles, and may be disposed within the container. Pharmaceutical product may be enclosed within one or more of these receptacles. The pharmaceutical product receiver may be locked to at least some degree within the container to facilitate disposal of the pharmaceutical product supply, for instance at a time when some of the pharmaceutical product may have been removed from the pharmaceutical product receiver but prior to utilizing all of the pharmaceutical product originally provided with the pharmaceutical product receiver.

Abstract: There is provided a method for the synthesis of norbuprenorphine, and ultimately buprenorphine, utilizing oripavine as the starting material. Conventional methods of producing buprenorphine utilize thebaine as the starting material, requiring an O-demethylation step, typically a low to moderate yield transformation. The present use of oripavine as a starting material does not require an O-demethylation step, since the oripavine molecule lacks an O-3 methyl group.

Abstract: The invention relates to an adapter for a syringe plunger. The adapter of some embodiments may include a first side adapted to interface with a syringe plunger and an opposing a second side adapted to interface with a drive ram of a medical fluid injector. The adapter may include a peripheral side surface exhibiting a thickness and may include what may be characterized as at least one mating section adapted to engage with the syringe plunger. The mating section(s) may include a channel extending through the entire thickness of the adapter. In some embodiments, the mating section(s) may include a stop adjacent the channel that extends less than the entirety of the thickness of the adapter.

Abstract: Systems and methods are presented for the visual indication of whether a power injector has discharged fluid from a power injector syringe in a previous medical procedure. In this regard, the systems and methods generally provide for a power injector and a syringe for use with the power injector. The syringe includes a visual indicator that moves between a first state and a second state at approximately the same time that the power injector discharges fluid from the syringe such that an operator may view the change in state.

Abstract: Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.

Abstract: A system for assaying an eluate for Technetium-99m and Molybdenum-99 content includes an inner ionization chamber including a well configured to receive the eluate, an outer ionization chamber concentric with the inner ionization chamber, and attenuating material positioned between the inner and outer ionization chambers. A computing device is configured to determine a Technetium-99m content of the eluate based on a first current measured in the inner ionization chamber, and determine a Molybdenum-99 content of the eluate based on at least a second current measured in the outer ionization chamber.

Abstract: The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions.

Abstract: The present invention provides (+)-morphinanium compounds comprising substituted 6-hydroxy or 6-amine groups. The invention also provides methods for inhibiting microglial activation by administering the compounds of the invention.

Abstract: The present disclosure generally related to an improved process for the preparation of various piperidine derivatives. More particularly, the present disclosure related to an improved process for preparing sufentanil base (1) and related compounds, which advantageously utilizes more cost effective and/or less hazardous reagents, including a dispersion comprising between about 50% and about 70% by weight (based on the total weight of the dispersion) of an alkali metal hydride, such as sodium hydride, as well as eliminates the need for expensive and/or time consuming purification techniques.

Abstract: Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.

Abstract: A contrast media injection system includes detects the absolute position of the syringe ram using a non-contact sensor. A series of magnets and Hall-Effect sensors may be used or an opto-reflective system. Illuminated knobs that are connected to the drive mechanism for the syringe ram rotate with the drive and provide visual feedback on operation through the illumination. Analog Hall-Effect sensors are used to determine the presence or absence of magnets that identify the type of faceplate being used. The faceplates include control electronics, connected to the powerhead through connectors, which may be interchangeably used by the two faceplates. The faceplate electronics include detectors for automatically detecting the capacity of pre-filled syringes.

Abstract: Various sealing structures are used in a front-loading injector, for preventing leakage of spilled fluid from an external surface of a syringe into the vicinity of the drive ram. For example, a sealing gasket may be incorporated into the front face of the injector housing, for mating to the rearward circular edge of the cylindrical body of a syringe. Alternatively, sealing and locking functions may be performed by a single structure on the rearward end of the syringe. Further, leakage may be prevented by including a non-planar sealing flange on the syringe, positioned on the syringe forward of the locking structure, or by a two-piece structure, including a syringe and a separate leakage stopping washer for surrounding the syringe to halt the flow of fluid along the exterior of the syringe. (As part of this aspect, or as an independent feature, the syringe may include an annularly discontinuous flange forward of the locking structure, for providing mechanical support for the syringe against the injector.

Abstract: A flow rate assessment protocol (140) that may be utilized by a power injector (10) is disclosed. This flow rate assessment protocol (140) monitors a flow rate (156) during execution of a medical fluid delivery protocol (154). This monitored flow rate is compared with a target flow rate (158). A comparative output of this monitored flow rate and target flow rate is displayed (160), for instance on a graphical user interface (11).

Abstract: A transdermal patch container (10) that includes a container body (16), a first compartment (24), and a second compartment (28) is disclosed. One or more first transdermal patches (34) may be stored in the first compartment (24). One or more second transdermal patches (36) may be stored in the second compartment (28). The first transdermal patches (34) differ from the second transdermal patches (36) in at least one respect. A number of features may be incorporated to reduce the potential of being able to withdraw second transdermal patches (36) out of the second compartment (28). For instance, second transdermal patches (36) may be required to be directed through a slot (44) to enter a second compartment (28i). A flap (66) may be positioned below such a slot (58) within a second storage compartment (28ii). A plurality of vertically spaced or staggered flaps (96) may be positioned within a second storage compartment (28iv).

Abstract: Various embodiments of pharmaceutical product containers are disclosed. Each pharmaceutical product container includes a cap, a container body, and a locking mechanism. The locking mechanism is disposable from a locked state to an unlocked state at least when the cap is in a closed position relative to the container body (e.g., to define an enclosed space for pharmaceutical product). Once in the locked state and with the cap being in a closed position, the locking mechanism is unable to return to its unlocked state. Pharmaceutical product enclosed within the container with the locking mechanism being in its locked state may then be disposed of in any appropriate manner (e.g., discarded in the trash).

Abstract: The present invention provides an efficient process for the preparation of hexahydroisoquinolines from amides. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines.

Abstract: An auto purge for an intravenous contrast injector of the type having a motor which advances a plunger drive ram and configured for use with a pre-filled or user-filled syringe containing an approximate known amount of air including a processor which causes the motor to move and a memory storing a predetermined purge stop point representative of the approximate known amount of air in the syringe, the injector configured to automatically advance the plunger drive ram an amount substantially equal to the predetermined purge stop point representative of the approximate known amount of air contained in the syringe.